Asia Tech Wire (Oct 8) -- Novo Nordisk and Viatris' Mylan have agreed to settle patent disputes related to Novo Nordisk's weight-loss drugs Ozempic and Wegovy, the two companies said in a joint filing.

The Danish drugmaker had previously sued Viatris and other companies separately in court for patent infringement in an effort to block proposed generics.

A Novo Nordisk spokesperson confirmed the settlement agreement on Monday.